← All trials
NCT04817956
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 1, 2021
- Primary completion
- Mar 30, 2040
- Completion date
- Apr 30, 2045
- First posted
- Mar 26, 2021
- Last posted
- Apr 30, 2021
- Enrollment
- 1000
- Arms / groups
- 7 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of OsloLead sponsor
- University of OsloReponsible party - principal investigator
- University of OsloOverall official - principal investigator
- Vestre Viken Ringerike SykehusCollaborator
- Norwegian University of Science and TechnologyCollaborator
- University of StavangerCollaborator
- University Hospital of North NorwayCollaborator
- The Hospital of VestfoldCollaborator
- Oslo Metropolitan UniversityCollaborator
- University of BergenCollaborator
- Northern Norway Regional Health AuthorityCollaborator
- Nordland HospitalCollaborator
- South-Eastern Norway Regional Health AuthorityCollaborator
- Telemark Hospital TrustCollaborator
- Hospital of Southern Norway TrustCollaborator
- Helse Møre og Romsdal HFCollaborator
- Sykehuset Innlandet HFCollaborator
- Helse FordeCollaborator
- Helse FonnaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.